Navigation Links
Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes
Date:5/18/2009

ORLANDO, May 18 /PRNewswire-USNewswire/ -- A pill used for nerve pain offers women relief from hot flashes, Mayo Clinic researchers report at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

They say the agent, pregabalin, decreased hot flash severity and frequency about 20 percent more than did a placebo agent. Thus, pregabalin appears to offer about the same benefit as gabapentin, an older, related drug, as well as newer classes of antidepressants.

"Hot flashes are a major problem in many women, and for those who opt not to take hormonal therapies or antidepressants, pregabalin appears to be another treatment option," says the study's lead author, Charles Loprinzi, M.D., a medical oncologist at the Mayo Clinic in Minnesota.

While pregabalin offers about the same benefit as gabapentin, women who use it only need to take two pills a day, versus three for gabapentin, he says. Side effects can occur with the use of either drug. However, in this study, they were not severe enough that participants stopped using the active study drug any more often than did patients who were taking placebos, researchers say.

Dr. Loprinzi has pioneered the field of nonhormonal hot flash therapy, which he began researching decades ago to help breast cancer patients using tamoxifen, an anti-estrogen treatment that creates symptoms of menopause. He is the first researcher to test the use of antidepressants, compared to placebo treatment, for hot flashes.

Gabapentin, an agent that has long been on the market to treat pain caused from injury to nerves, has been shown to decrease hot flashes more than do placebos. This drug is approved by the Food and Drug Administration (FDA) to treat diabetic peripheral neuropathy and for shingles; anecdotal evidence suggested that menopausal women who used it had a reduction in hot flashes, Dr. Loprinzi says. Multiple placebo-controlled studies have since demonstrated that this drug decreases hot flashes.

Gabapentin and a variety of antidepressants are now commonly prescribed for treatment of hot flashes, although these agents are not specifically approved by the FDA for such use.

Pregabalin is a newer version of gabapentin. "We thought it might also relieve hot flashes and thus was worth testing," Dr. Loprinzi says.

So, using funds from the National Cancer Institute, Dr. Loprinzi and colleagues set up a 207-participant study conducted by the North Central Cancer Treatment Group (NCCTG). The study was a Phase III double-blinded, placebo-controlled randomized trial, testing three different treatment arms: a placebo versus daily doses of 150 milligrams (mg) of pregabalin (75 mg twice a day) and 300 milligrams (150 mg twice a day). Patients getting pregabalin started off with lower doses which were increased weekly to the eventual full dose.

Participants, who reported having at least 28 hot flashes a week, kept a "hot flash diary" in which they recorded the number and severity of hot flashes they had each day while taking their study drug -- the content of which was unknown to them.

In the study group, 34 percent were using anti-estrogen therapy -- either an aromatase inhibitor, raloxifene, or tamoxifen -- to help prevent the recurrence of estrogen-sensitive breast cancer.

The researchers found that for the 163 patients for whom information was available, both doses of pregabalin reduced hot flashes to about the same degree, but that toxicities, such as cognitive dysfunction, were increased at the higher dose. Other reported side effects included weight gain, sleepiness, dizziness, coordination troubles, concentration troubles, and concerns regarding vision changes.

They found that, after six weeks of treatment, women using a placebo agent reported about a 50 percent decrease in their hot flash score (severity), but the change was greater for those who used a 75-milligram twice daily dose of pregabalin (65 percent decrease) and a 150-milligram twice daily dose (71 percent decrease). The declines in hot flash frequency were 36 percent for placebo users, 58 percent in women who used lower-dose pregabalin, and 61 percent in women given the higher dose.

"All in all, this study demonstrates that we have another agent to add to the list of medications that offer benefit against hot flashes, even in women using anti-estrogen therapies," Dr. Loprinzi says.

Pfizer, the company that manufactures pregabalin, donated both the drug and placebo tablets for this study.

About Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,300 physicians, scientists and researchers and 46,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education, visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.

VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Charles Loprinzi describing the research, are available on the Mayo Clinic News Blog.


'/>"/>
SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report
2. Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators
3. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
4. Frost & Sullivan: Clinical and Cost Benefits to Promote Uptake of Advanced Wound Management Technologies Across Europe
5. Large clinical trial finds pirfenidone may help lung function in IPF patients
6. Fewer Than One Percent of Infertile Couples Who Need Treatment Receive It - Website to Bridge Gap Between Infertile Couples and Fertility Clinics
7. Cleveland Clinic CIO Named to Federal Advisory Committee on Health Information Technology
8. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
9. Cigna Medical Group Announces Grand Opening of CareToday Clinic in Anthem, Ariz.
10. Mayo Clinic researchers say agent provides treatment option for women with hot flashes
11. BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology: